Skip to main content

Table 4 Summary of treatment-emergent AEs (CE population)

From: Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials

Number of patients with ≥ 1,
n (%)
All patients High-risk
CAP HAP (excluding VAP) CAP HAP (excluding VAP)
Ceftobiprole
(n = 231)
Ceftriaxone ± linezolid
(n = 238)
Ceftobiprole
(n = 198)
Ceftazidime plus linezolid (n = 185) Ceftobiprole
(n = 193)
Ceftriaxone ± linezolid
(n = 205)
Ceftobiprole
(n = 169)
Ceftazidime plus linezolid (n = 138)
AE 163 (70.6) 149 (62.6) 141 (71.2) 140 (75.7) 138 (71.5) 133 (64.9) 126 (74.6) 112 (81.2)
SAE 23 (10.0) 24 (10.1) 53 (26.8) 39 (21.1) 21 (10.9) 22 (10.7) 51 (30.2) 33 (23.9)
Treatment-related AE 82 (35.5) 61 (25.6) 51 (25.8) 49 (26.5) 70 (36.3) 57 (27.8) 46 (27.2) 43 (31.2)
Treatment-related SAE 2 (0.9) 3 (1.3) 7 (3.5) 3 (1.6) 2 (1.0) 2 (1.0) 7 (4.1) 3 (2.2)
SAE leading to death 3 (1.3) 6 (2.5) 27 (13.6) 28 (15.1) 3 (1.6) 6 (2.9) 26 (15.4) 25 (18.1)
  1. AE adverse event, CAP community-acquired pneumonia, CE clinically evaluable, HAP hospital-acquired pneumonia, SAE serious adverse event, VAP ventilator-associated pneumonia